Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jun 12, 2023
Deals
Seeking high-value drugs, Novartis adds kidney franchise in $3.2B Chinook takeout
Biotech’s later-stage candidates give pharma two chances at a blockbuster, starting with IgA nephropathy indication amid rising competition
BioCentury | Apr 11, 2023
Finance
April 11 Quick Takes: VintaBio debuts with $64M to tackle viral vector bottleneck
Plus: Moderna forecasts up to $15B in 2027 sales of respiratory franchise and updates from HI-Bio, Chinook, Impact-Junshi and more
BioCentury | Nov 18, 2021
Deals
Eyeing RNAi platform more than pipeline, Novo buys Dicerna for $3.3B
Building on prior deal around hepatic platform, takeout gives Novo broader access to Dicerna’s technology
BioCentury | Aug 27, 2021
Distillery Therapeutics
A necroptosis and ferroptosis inhibitor for acute kidney injury
BioCentury | Aug 6, 2021
Product Development
Aug. 6 Quick Takes: Sanofi gains FDA approval for Pompe therapy
Plus: Adagio’s NASDAQ debut, setbacks weigh on Dicerna, Novavax, Spectrum stocks, a deal for Oyster Point, Ji Xing and more
BioCentury | Jul 17, 2021
Product Development
The growing siRNA pipeline: Data Byte
At least 37 companies are developing small interfering RNA (siRNA) therapies to treat genetic and rare diseases, with more than half moving into clinical trials. Of the products being explored by
BioCentury | Aug 28, 2020
Distillery Therapeutics
Potassium channel-vesicle interaction as a target in ischemic stroke
DISEASE CATEGORY: Neurology
INDICATION: Stroke Interrupting the interaction between the potassium channel KCNB1 and VAPA, a vesicle membrane protein, could treat ischemic stroke. In cultured rat
INDICATION: Stroke Interrupting the interaction between the potassium channel KCNB1 and VAPA, a vesicle membrane protein, could treat ischemic stroke. In cultured rat
BioCentury | Aug 11, 2020
Product Development
Remdesivir heads for FDA review as Gilead continues to build manufacturing pipeline
Plus data from Omeros, PTC and a call to make mAbs accessible
Items per page:
1 - 10 of 107